Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment

Progress in Cardiovascular Diseases

Volumn 58, Issue 5, 2016, Pages 483-494

  Tornyos, Adrienn ^a   Kehl, Dániel ^a   D'Ascenzo, Fabrizio ^b   Komócsi, András ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Myocardial infarction; Network metanalysis; Non vitamin K antagonist oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG SAFETY; EMBOLISM; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; COMPLICATION; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; MYOCARDIAL INFARCTION; NETWORK META-ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PULMONARY EMBOLISM; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; NETWORK META-ANALYSIS; ODDS RATIO; PATIENT SAFETY; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84954290696     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.12.001     Document Type: Review

References (46)

1. Windecker S., Kolh P., Alfonso F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35(37):2541-2619.
2. D'Ascenzo F., Taha S., Moretti C., et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol 2015, 115(9):1185-1193.
3. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383(9921):955-962.
4. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
5. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
6. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
7. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172(5):397-402.
8. Chatterjee S., Sharma A., Uchino K., Biondi-Zoccai G., Lichstein E., Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis 2013, 24(8):628-635.
9. Tornyos A., Vorobcsuk A., Kupo P., Aradi D., Kehl D., Komocsi A. Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2014, 40(1):1-11.
10. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
11. Brown S., Hutton B., Clifford T., et al. A Microsoft-Excel-based tool for running and critically appraising network meta-analyses-an overview and application of NetMetaXL. Syst Rev 2014, 3:110-120.
12. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295(13):1519-1530.
13. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362(9397):1691-1698.
14. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003, 146(3):431-438.
15. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369(9):799-808.
16. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363(26):2499-2510.
17. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366(14):1287-1297.
18. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361(24):2342-2352.
19. Fiessinger J.N., Huisman M.V., Davidson B.L., et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005, 293(6):681-689.
20. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368(8):709-718.
21. Perk J., De B.G., Gohlke H., et al. European GUIDELINES on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012, 33(13):1635-1701.
22. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817.
23. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373(9678):1849-1860.
24. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329-1339.
25. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.
26. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
27. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354(16):1706-1717.
28. Roe M.T., Armstrong P.W., Fox K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012, 367(14):1297-1309.
29. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367(9526):1903-1912.
30. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370(9586):493-503.
31. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343(8899):687-691.
32. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342(8882):1255-1262.
33. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347(13):969-974.
34. van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360(9327):109-113.
35. Andreotti F., Testa L., Biondi-Zoccai G.G., Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006, 27(5):519-526.
36. Dewilde W.J., Janssen P.W., Verheugt F.W., et al. Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. J Am Coll Cardiol 2014, 64(12):1270-1280.
37. Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012, 125(5):669-676.
38. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010, 363(19):1875-1876.
39. Food and Drug Administration FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin 2014, [press release].
40. Larsen T.B., Rasmussen L.H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61(22):2264-2273.
41. Larsen T.B., Rasmussen L.H., Gorst-Rasmussen A., et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014, 127(4):329-336.
42. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366(1):9-19.
43. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365(8):699-708.
44. Komocsi A., Vorobcsuk A., Kehl D., Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012, 24:1-9.
45. Glund S., Stangier J., Schmohl M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015, 386(9994):680-690.
46. Pollack C.V., Reilly P.A., Eikelboom J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015, 373(6):511-520.